PubMed
Prolonged stimulation of growth hormone (GH) secretion after a single administration of CJC-1295
Teichman SL, Neale A, Lawrence B, et al. J Clin Endocrinol Metab. 2006
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
810 users report co-tracking this pair (26% of CJC-1295 trackers also track Ipamorelin).
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 64% · Mixed 18% · Unfavorable overall 18%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg
Reports span 0.1–2 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 59% said they felt similar to their last entry, 44% more positive, and 14% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 24 days · Based on 147 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 44% · Mixed 46% · Unfavorable overall 10%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg
Reports span 0.1–2 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 54% said they felt similar to their last entry, 30% more positive, and 14% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 31 days · Based on 117 repeat reporters
Published sources linked on the CJC-1295 and Ipamorelin wiki pages.
PubMed
Teichman SL, Neale A, Lawrence B, et al. J Clin Endocrinol Metab. 2006
PubMed
Ghigo E, Arvat E, Camanni F. Endocrine. 2008
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Johansen PB, Nowak J, Skjaerbaek C, et al. Eur J Endocrinol. 2001
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Raun K, Hansen BS, Johansen NL, et al. European journal of endocrinology. 1998
PubMed
Lu Z, Ngan MP, Liu JYH, et al. Physiology & behavior. 2024